Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Abstract Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment response. Immunohistochemical quantifi...

Full description

Bibliographic Details
Main Authors: Jason Zhu, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, Tian Zhang
Format: Article
Language:English
Published: BMJ Publishing Group 2018-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-L1
Biomarkers
Immune checkpoint inhibition
Urothelial carcinoma
Renal cell carcinoma
Online Access:http://link.springer.com/article/10.1186/s40425-018-0314-1

Internet

http://link.springer.com/article/10.1186/s40425-018-0314-1

Similar Items